Ignite Creation Date:
2024-05-06 @ 4:27 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT04999202
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-12
First Post:
2021-08-05
Brief Title:
A Study to Learn How Safe the Study Drug BAY 2416964 AhR Inhibitor in Combination With the Treatment Pembrolizumab is How This Combination Affects the Body the Maximum Amount That Can be Given How it Moves Into Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Sponsor:
Organization:
Bayer
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
47
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: